Cancer - Prostate(구연) (E-109) [F-18]Florastamin PET/CT for prostate cancer screening of men with low to intermediate PSA levels: a Pilot study Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Nuclear medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Urology, The Catholic University of Korea, Seoul St. Mary's Hospital, Nuclear medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Urology, The Catholic University of Korea, Seoul St. Mary's Hospital Hyong Woo Moon, Sonya Youngju Park, Yong Hyun Park, Woong Jin Bae, Hyuk Jin Cho, U-Syn Ha, Sung-Hoo Hong, Sae Woong Kim, Ie Ryung Yoo, Ji Youl Lee Background: Research on PSMA PET/CT and pending FDA approval are predominantly aimed towards biochemical recurrence, rather than presurgical staging. Studies on the latter indication have almost exclusively investigated biopsy-proven cancers. / Objectives: We herein present the first in-man clinical evaluation of a novel F-18 labelled PSMA ligand, Florastamin, in screening for prostate cancer. / Materials and Methods: We recruited 2 men with PSA levels between 3 (the threshold for biopsy) and 20 n/mL. A mean dose of 267-370 MBq (8-10 mCi) was administered. Whole-body images were acquired at 90 minutes postinjection, followed by an additional pelvic PET/CT acquisition 30 minutes later. Conventional imaging (MRI) was performed within one week of, usually preceding, the PET/CT. PET/CT findings were compared to preoperative diagnostic MRI and correlated with final biopsy pathology.   / Results and Conclusion: Tweny-one patients, who had a median PSA of 7.02 ng/mL (range 3.24-18.6) were endolled in this study. Thirteen patients were biopsy-proven with prostate cancer, of which four were low-risk and nine were intermediate risk. PET/CT visual analysis identified abnormal [F-18]Florastamin uptake in at least one primary prostatic tumor focus in 11/13 patients at 90 minutes and 12/13 patients at 120 minutes. The sensitivity, specificity and accuracy was 45.8%, 37.2% and 89.9% for MRI, and 3.3%, 99.3% and 97.0% for [F-18]Florastamin at 60 minutes, respectively. Delayed imaging showed comparable accuracy.  [F-18]Florastamin is a promising PET tracer that correctly identifies foci of cancer within the prostate with a higher acuracy that conventional imaging (MRI), and may be helpful in stratification of patients with low to intermediate PSA levels to better assess the need for an invasive biopsy.